US LNG exports surge but will buyers in China turn up?
IRVINE, AYRSHIRE - RUA Life Sciences plc, the parent company of a portfolio of medical device businesses, has moved its registered office and UK head office to a new location in Irvine, Ayrshire. The change took effect on April 30, 2025, as the company transitions from its previous address in Glasgow.
The new head office is situated at 2 Drummond Crescent, Riverside Business Park, Irvine, Ayrshire, KA11 5AN. This move is part of the company’s ongoing operational developments. RUA Life Sciences is known for its focus on the exploitation of Elast-EonTM, which is considered the world’s leading long-term implantable biostable polymer.
RUA Life Sciences’ activities include the exploitation of its intellectual property and know-how, medical device contract manufacturing, and the development of medical devices. The company operates within the healthcare sector, which is subject to stringent regulations and continuous innovation.
The announcement of the change of address was made without additional details regarding the reasons for the move or the strategic implications for the company’s operations. As the holding company for a group focused on medical device innovation, such relocations are not uncommon in the industry and often reflect organizational growth or shifts in strategic focus.
Investors and stakeholders can contact the company’s executives, including Chief Executive Bill Brown and Group Chief Financial Officer Lachlan Smith, for further information. The company’s nominated adviser and broker, Cavendish Capital Markets Limited, is also available for contact.
This news about RUA Life Sciences’ new registered office is based on a press release statement and does not include any marketing promotion or subjective claims. The company continues to maintain its presence in the medical device market, with a focus on leveraging its proprietary technology for long-term implantable devices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.